Probiotics in Inflammatory Bowel Diseases and Associated Conditions
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
A complex set of interactions between the human genes encoding innate protective functions and immune defenses and the environment of the intestinal mucosa with its microbiota is currently considered key to the pathogenesis of the chronic inflammatory bowel diseases (IBD). Probiotics offer a method to potentially alter the intestinal microbiome exogenously or may provide an option to deliver microbial metabolic products to alter the chronicity of intestinal mucosal inflammation characterizing IBD. At present, there is little evidence for the benefit of currently used probiotic microbes in Crohn’s disease or associated conditions affecting extra-intestinal organs. However, clinical practice guidelines are now including a probiotic as an option for recurrent and relapsing antibiotic sensitive pouchitis and the use of probiotics in mild ulcerative colitis is provocative and suggests potential for benefit in select patients but concerns remain about proof from trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 2×
“similar maintenance of remission rate as the probiotic intervention group [40,41].”
BackgroundResultProphylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S. J. H., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.028 · Cited by 786
Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’Neil, D. A., & Macfarlane, G. T. (2005) · Gut · doi:10.1136/gut.2004.044834 · Cited by 766
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513 · cited 1×
“coli Nissle) 1–4 × 10 9 2–8 [36] 147 (77) DBRPC Blend Probiotic (VSL#3TM) 7.”
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462
Gupta, P., Andrew, H., Kirschner, B. S., & Guandalini, S. (2000) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200010000-00024 · Cited by 429
Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397 · cited 3×
“20 (10) EBRPC Blend Probiotic (YakultTM) 1 × 10 10 12 [28]”
BackgroundMethodProbiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study
Vleggaar, F. P., Monkelbaan, J. F., & van Erpecum, K. J. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f5197e · Cited by 110
Cited by
Probiotics, gut microbiota and health
Butel, M.-J. (2014) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2013.10.002 · Cited by 457
Probiotics, prebiotics and amelioration of diseases
Tsai, Y.-L., Lin, T.-L., Chang, C.-J., Wu, T.-R., Lai, W.-F., Lu, C.-C., & Lai, H.-C. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-018-0493-6 · Cited by 388
Probiotics in Medicine: A Long Debate
Stavropoulou, E., & Bezirtzoglou, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02192 · Cited by 282
The microbiota in inflammatory bowel disease: Current and therapeutic insights
Lane, E. R., Zisman, T., & Suskind, D. (2017) · Journal of Inflammation Research · doi:10.2147/jir.s116088 · Cited by 226
“Probiotics, as a whole, have not demonstrated efficacy in the treatment of CD; however, there may be some role for the use of specific probiotics in the management of mild-to-moderate active UC or recurrent pouchitis after ileoanal anastomosis.(110) VSL#3 is a highly-concentrated probiotic preparation that contains ei…”
Considerations for determining safety of probiotics: A USP perspective
Roe, A. L., Boyte, M.-E., Elkins, C. A., Goldman, V. S., Heimbach, J., Madden, E., Oketch-Rabah, H., Sanders, M. E., Sirois, J., & Smith, A. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105266 · Cited by 136
“Although probiotics at high concentrations have not revealed safety concerns actual exposure to the probiotic should be recorded (Alisi et al., 2014; Guandalini et al., 2010; Mack, 2011; EMA, 1996).”
Background
Metadata
- Authors
- Mack, D. R.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2011-02-17
- Volume
- 3
- Issue
- 2
- Pages
- 245-264
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2040986764
- Cited by
- 78
- References
- 10
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.